GlaxoSmithKline (NYSE:GSK) has agreed to pay $229M to settle lawsuits with eight states that accused the company of misrepresenting the safety and efficacy of its diabetes treatment Avandia, which has been connected to an increased risk of heart attacks and strokes. The deal adds to a $90M settlement with 37 other states and the District of Columbia over Avandia, not to mention a $3B agreement with Federal authorities over the drug and other pharmaceuticals.